Friday, 20 Nov 2009 | Source: The Associated Press
Biotechnology company Dendreon Corp. said Friday the Food and Drug Administration will make a regulatory decision on the potential prostate cancer vaccine Provenge by May 1.
No doubt the widespread use of solar and wind power is ideal, but it’ll be a long time before the mass adoption of those alternative energies is a reality. In the meantime, Cramer says, the US should shift its focus to natural gas.
Dendreon has completed its U.S. regulatory submission for its closely watched experimental prostate cancer vaccine, the company said Monday, sending its shares up 5 percent.
Investors, patients and activists, no doubt, hope they won't have to put out a mayday distress call, but as Dendrama's fate would have it, the company announced today that the Food and Drug Administration has assigned May Day as its decision day for the prostate cancer treatment Provenge.... Read More